Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086359 · ClinicalTrials.gov registry record · Phase 3
Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
NCT00086359 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 19 participants.
The verdict
NCT00086359, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
Study Summary
Pregnant women infected with HIV who take anti-HIV medications during pregnancy lower the risk of passing HIV to their infants. This study will compare how well two different combinations of anti-HIV medications control HIV in pregnancy, and whether these combinations of drugs are effective in preventing HIV from being transmitted from a pregnant woman to her baby. The two combinations are abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) and zidovudine/lamivudine (ZDV/3TC) plus lopinavir/ritonavir (LPV/RTV).
Interventions
- DRUG Lopinavir/ritonavir
- DRUG Lamivudine/zidovudine
- DRUG Abacavir sulfate, lamivudine, and zidovudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-07 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086359
The ClinicalTrials.gov registry entry for NCT00086359 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lopinavir/ritonavir is the first listed.
NCT00086359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00086359 about?
NCT00086359 is a clinical study titled "Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV". Pregnant women infected with HIV who take anti-HIV medications during pregnancy lower the risk of passing HIV to their infants. This study will compare how well two different combinations of anti-HIV medications control HIV in pregnancy, and whether these combinations of drugs are effective in preve...
What is the current status of trial NCT00086359?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2004-07. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00086359?
The interventions under investigation include: Lopinavir/ritonavir (DRUG), Lamivudine/zidovudine (DRUG), Abacavir sulfate, lamivudine, and zidovudine (DRUG).
Who is sponsoring clinical trial NCT00086359?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.